Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | IDE | P14735 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.33 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.32 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211084 | 0.89 | SUV39H2 (0.36) | SUV39H2CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL35211460 | 0.89 | SUV39H2 (0.36) | SUV39H2CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL35211098 | 0.89 | SUV39H2 (0.36) | SUV39H2CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL35212635 | 0.88 | CCR1 (0.33) | SUV39H2CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL35212419 | 0.86 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212310 | 0.86 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212133 | 0.86 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35212385 | 0.86 | LMNA (0.34) | LMNAMAPK1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL35211730 | 0.85 | SUV39H2 (0.33) | SUV39H2CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL35211716 | 0.85 | CACNB4 (0.34) | SUV39H2CACNB4CACNA1ACACNA1GCACNG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | LMNA 1019/4885MAPK1 1919/4885SMN1; SMN2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.